NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity
Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a
publicly-traded special purpose acquisition company, announced
today the results of its special meeting of shareholders, which was
held on March 17, 2021.
At the special meeting, shareholders of the Company approved the
merger, including a certain agreement and plan of merger, dated as
of October 21, 2020, by and among
4d pharma plc, the Company and
Dolphin Merger Sub Limited, and the related agreements and
transactions contemplated thereby.
About LOAC
LOAC is a blank check company, also commonly referred to as a
Special Purpose Acquisition Company, or SPAC, formed for the
purpose of acquiring, engaging in a share exchange, share
reconstruction and amalgamation, purchasing all or substantially
all of the assets of, entering into contractual arrangements, or
engaging in any other similar business combination with one or more
businesses or entities. LOAC is contemplating a proposed business
combination with 4d pharma plc
(AIM: DDDD), a public limited company incorporated under the laws
of England and Wales pursuant to an agreement and plan of
merger dated October 21, 2020 as
disclosed in a Form 8-K filed with the Securities and Exchange
Commission on October 22, 2020. LOAC
is sponsored by Whale Management Corporation, a BVI business
company with limited liability.
About 4d pharma
Founded in February 2014,
4d pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx®, that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4d pharma's Live Biotherapeutic
products (LBPs) are orally delivered single strains of bacteria
that are naturally found in the healthy human gut. The Company has
six clinical programmes, namely a Phase I/II study of MRx0518 in
combination with KEYTRUDA® (pembrolizumab) in solid tumours, a
Phase I study of MRx0518 in a neoadjuvant setting for patients with
solid tumours, a Phase I study of MRx0518 in patients with
pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a
Phase II study of MRx-4DP0004 in patients hospitalised with
COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has
completed a successful Phase II trial. Preclinical-stage programmes
include candidates for CNS disease such as Parkinson's disease and
other neurodegenerative conditions. The Company has a research
collaboration with MSD, a tradename of Merck & Co., Inc.,
Kenilworth, NJ, USA, to discover
and develop Live Biotherapeutics for vaccines.
In October 2020 4d pharma announced its intention to merge
with Longevity Acquisition Corporation (NASDAQ: LOAC), a special
purpose acquisition company (SPAC), and seek a NASDAQ listing. The
merger is expected to be completed and the NASDAQ listing of
4d pharma American Depositary
Shares (ADSs) under the ticker symbol 'LBPS' is currently expected
to become effective in early 2021, subject to approval of 4D
Shareholders and Longevity Shareholders, and the SEC review
process.
For more information, refer to https://www.4dpharmaplc.com
Forward-Looking Statements
This press release and the exhibits hereto include
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995 and within the meaning of Section 27a of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Any actual results may differ from expectations,
estimates and projections presented or implied and, consequently,
you should not rely on these forward-looking statements as
predictions of future events. Words such as "expect," "estimate,"
"project," "budget," "forecast," "anticipate," "intend," "plan,"
"may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions are intended to
identify such forward-looking statements. These forward-looking
statements include, without limitation, LOAC's expectations with
respect to future performance, anticipated financial impacts of the
proposed business combination, approval of the business combination
transactions by security holders, the satisfaction of the closing
conditions to such transactions and the timing of the completion of
such transactions.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, or a solicitation
of any vote or approval, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the U.S. Securities Act of 1933, as
amended.
INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN
APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY
AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS
OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION
CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
Contact:
Matthew Chen
Longevity Acquisition Corporation
+ (86) 21-60832028
mchen@lonacq.com
View original
content:http://www.prnewswire.com/news-releases/longevity-acquisition-corporation-announces-results-of-special-meeting-of-shareholders-301250169.html
SOURCE Longevity Acquisition Corporation